echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Qilu enters the market with annual sales of $1.9 billion blockbuster drugs and Chengdu Beite competes for the first imitation

    Qilu enters the market with annual sales of $1.9 billion blockbuster drugs and Chengdu Beite competes for the first imitation

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 7, Qilu Pharmaceuticals applied for the 4 types of generic listing applications for emtricitabine propofol tenofovir tablets (I) and emtricitabine propofol tenofovir tablets (II).
    At present, there are only original research in China.
    Drugs were approved for import in 2018, and no domestic generic drugs have been approved for the time being

    .


    Gilead’s emtricitabine propofol tenofovir is suitable for use in combination with other antiretroviral drugs to treat human immunodeficiency virus type 1 ( HIV-1) infection
    .
    The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
    9 billion U.
    S.
    dollars

    .


    In 2018, NMPA approved Gilead’s fixed-dose compound formulation emtricitabine propofol tenofovir tablets (I: emtricitabine 200mg/ propofol tenofovir 10mg, II: emtricitabine 200mg/ propofol Tenofovir 25mg) is used for HIV treatment
    .
    According to data from Menet.
    com, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2020.
    487.
    61%, and the growth rate of physical pharmacies in Chinese cities is also as high as 177.
    78%.
    The rapid increase of original research products in the domestic market has also attracted the attention of domestic pharmaceutical companies

    .


    Chengdu Better Pharmaceuticals submitted an application for the imitation of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval
    .
    From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end

    .
    (
    Minenet )


    The review data statistics are as of June 7.
    If there are any errors or omissions, please correct me

    .

    On June 7, Qilu Pharmaceuticals applied for the 4 types of generic listing applications for emtricitabine propofol tenofovir tablets (I) and emtricitabine propofol tenofovir tablets (II).
    At present, there are only original research in China.
    Drugs were approved for import in 2018, and no domestic generic drugs have been approved for the time being

    .


    Gilead’s emtricitabine propofol tenofovir is suitable for use in combination with other antiretroviral drugs to treat human immunodeficiency virus type 1 ( HIV-1) infection
    .
    The compound preparation was approved by the FDA in 2016 and its global sales in 2020 will be close to 1.
    9 billion U.
    S.
    dollars

    .


    In 2018, NMPA approved Gilead’s fixed-dose compound formulation emtricitabine propofol tenofovir tablets (I: emtricitabine 200mg/ propofol tenofovir 10mg, II: emtricitabine 200mg/ propofol Tenofovir 25mg) is used for HIV treatment
    .
    According to data from Menet.
    com, the sales growth rate of emtricitabine and propofol tenofovir will be at the terminals of Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) in 2020.
    487.
    61%, and the growth rate of physical pharmacies in Chinese cities is also as high as 177.
    78%.
    The rapid increase of original research products in the domestic market has also attracted the attention of domestic pharmaceutical companies

    .


    Chengdu Better Pharmaceuticals submitted an application for the imitation of emtricitabine propofol tenofovir tablets (acceptance number CYHS1900772) in November 2019, and the acceptance number is currently under review and approval
    .
    From the perspective of the contracting time, Qilu Pharmaceutical is slightly inferior, but we will continue to follow up and report whether it can make a comeback in the end

    .
    (
    Minenet )


    The review data statistics are as of June 7.
    If there are any errors or omissions, please correct me

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.